Salivary Proteome Changes in Relapsing-Remitting MS Patients
In a study involving patients with relapsing-remitting MS, researchers identified 1305 proteins in saliva, observing 209 differences between those undergoing disease-modifying therapy and healthy controls. Notable changes were seen after six months of therapy, indicating potential associations with immune response and cellular processes.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This research suggests that saliva may serve as a valuable biofluid for monitoring molecular changes in MS and could help in assessing treatment effects over time.
What this does not prove
However, the findings are purely descriptive and do not demonstrate direct pharmacological effects or correlate with clinical outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-10-19
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Patients with relapsing-remitting MS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceSalivary Proteomics Reveals Disease- and Therapy-Associated Molecular Patterns in Relapsing-Remitting Multiple Sclerosis. ↗DOI: 10.3390/biom16101524
Supporting passages (12)
sample size basisWe characterized the whole-saliva proteome of patients with relapsing-remitting (RR) MS at baseline before treatment initiation (MS-T0; n = 66) and after six months of disease-modifying therapy (MS-T1; n = 40), in comparison with healthy controls (HC; n = 31).
relevant ms typesRRMS
publication date2026-10-19
interventiondisease-modifying therapy
comparatorhealthy controls
primary endpointThese findings indicate that six months of therapy was associated with substantial salivary proteome changes and support saliva as a candidate biofluid for longitudinal molecular monitoring and non-invasive detection of treatment-associated salivary proteome variations in RRMS.
follow upsix months
findingsNano-liquid chromatography-high-resolution tandem mass spectrometry identified 1305 proteins, of which 209 differed among the main comparisons.
limitationsThe identified patterns are descriptive and cannot be interpreted as evidence of pharmacological treatment effects or clinical response.
populationWe characterized the whole-saliva proteome of patients with relapsing-remitting (RR) MS at baseline before treatment initiation (MS-T0; n = 66) and after six months of disease-modifying therapy (MS-T1; n = 40), in comparison with healthy controls (HC; n = 31).
peer reviewedPublication types: Journal Article
subjectsWe characterized the whole-saliva proteome of patients with relapsing-remitting (RR) MS at baseline before treatment initiation (MS-T0; n = 66) and after six months of disease-modifying therapy (MS-T1; n = 40), in comparison with healthy controls (HC; n = 31).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.